BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent

29-08-2023

Marisa Woutersen

BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent

Daniel Chetroni / Shutterstock.com

Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.


USPTO, BioNTech, Pfizer, Moderna, Covid-19, mRNA, vaccine, patent, pandemic, Comirnaty, Spikevax, US, Germany, Alnylam Pharmaceuticals

LSIPR